Originally published by our sister publication Clinical Oncology News
By Clinical Oncology News Staff
The FDA approved remestemcel-L-rknd (Ryoncil, Mesoblast), an allogeneic bone marrow–derived mesenchymal stromal cell (MSC) therapy, for steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months of age and older. Ryoncil is the first FDA-approved MSC therapy.
Efficacy was evaluated in MSB-GVHD001 (ClinicalTrials.gov. Identifier: NCT02336230), a multicenter,